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Dementia in Dementia with Lewy Bodies May
Not Be Attributable to Alzheimer Pathology
Jonathan M. Schott, MRCP,1
Andrew J. Lees, MD, FRCP,2
and Martin N. Rossor, MD, FRCP1
We read with interest the report by Gilman and colleagues
concerning the use of [11C]dihydrotetrabenazine positron emis-
sion tomography (PET) to differentiate dementia with Lewy
bodies (DLB) from Alzheimer’s disease (AD).1 We do, how-
ever, have some concerns regarding their use of terminology.
The authors divide DLB into those patients with demen-
tia preceding or starting at the same time as their movement
disorder, which they term DLB-AD, and those in which par-
kinsonism preceded the dementia, which they term DLB-
PD.1 The term DLB-AD implies that the dementia in DLB
is attributable or inevitably linked to Alzheimer’s disease. Al-
though a degree of Alzheimer pathology often accompanies
DLB, genetic studies demonstrate that dementia in Lewy
body Parkinson’s disease may occur in the absence of Alzhei-
mer pathology,2 and Alzheimer pathology is not always seen
in sporadic DLB: it is notable that in the one case of
DLB-AD coming to postmortem in Gilman and colleagues’
study, no AD pathology was found.1 The consensus criteria
for the diagnosis of DLB arbitrarily determine that patients
in whom dementia is unaccompanied by parkinsonism for
the first year be diagnosed with DLB and those in whom
motor features occur after the first year as having Parkinson’s
disease dementia (PDD).3 It is likely that these diseases are
on a continuum, a hypothesis that maybe supported by the
similar PET findings in both DLB-AD and DLB-PD re-
ported by Gilman and colleagues.1 Although the terms PDD
and DLB may be imperfect, we suggest that they may cause
less confusion than the terms DLB-PD and DLB-AD.
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Drs Schott, Lees, and Rossor express concern regarding the
terminology in our recent report describing the use of [11C]di-
hydrotetrabenazine with positron emission tomography (PET)
to differentiate dementia with Lewy bodies (DLB) from Alz-
heimer’s disease (AD).1 We divided the DLB cases into two
groups, 6 patients who developed parkinsonian features at least
1 year before dementia appeared (DLB/PD) and 14 who de-
veloped dementia before parkinsonism or at about the same
time (DLB/AD). They consider the abbreviations DLB/AD
and DLB/PD to be misleading, in that they regard the term
DLB/AD as implying that the dementia in DLB “is attribut-
able or inevitably linked to Alzheimer’s disease.” They would
have preferred that we used the consensus guidelines; however,
they appear to have misquoted these guidelines.2 They quote
the consensus criteria as recommending the diagnosis of DLB
for patients with dementia without parkinsonism for one year,
and the diagnosis of PDD for patients with dementia who de-
velop parkinsonism after the first year. The guidelines state, “…
if dementia occurs within 12 months of the onset of extrapyrami-
dal motor symptoms, the patient should be assigned a primary
diagnosis of possible DLB … If the clinical history of parkin-
sonism is longer than 12 months, PD with dementia … a more
appropriate diagnostic label …” (italics are ours).
When we were preparing our report, we discussed at
length the terminology recommended by the consensus
guidelines and decided against using it even though the def-
initions of the two groups we described conform to those
guidelines. Our reasons were that (1) the definitions of DLB
and PDD recommended by the consensus guidelines are
purely arbitrary; (2) the terms DLB and PDD imply different
neuropathological underpinnings to the disorders; (3) Alzhei-
mer pathology may or may not accompany widespread Lewy
body pathology in both DLB and PDD cases; and (4) apart
from comments on advanced AD, the guidelines do not ad-
dress the time course for presentation of parkinsonian symp-
toms after initial cognitive decline in DLB. Accordingly, we
selected abbreviations that we carefully defined in the article
to avoid any implication regarding the neuropathological
changes that might be found. As Dr Schott and colleagues
found our terminology to be confusing, perhaps we should
have used more neutral terms such as DLB-C for patients
who develop cognitive disorders in advance of parkinsonian
features and DLB-P for those who develop parkinsonian fea-
tures in advance of dementia.
1Department of Neurology, 2Division of Nuclear Medicine,
Department of Radiology, 3Department of Biostatistics, and
4Department of Psychiatry, University of Michigan, Ann
Arbor, MI
References
1. Gilman S, Koeppe RA, Little R, et al. Striatal monoamine ter-
minals in Lewy body dementia and Alzheimer’s disease. Ann
Neurol 2004;55:774–780.
2. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines
for the clinical and pathologic diagnosis of dementia with Lewy




604 © 2004 American Neurological Association
Published by Wiley-Liss, Inc., through Wiley Subscription Services
